Clinical study
Treatment Chronic UTI Post Kidney Transplant
| Status | Terminated |
|---|---|
| Type | Trial |
| Countries | Iran |
| Conditions studied | Urinary Tract Infections; Transplant-Related Disorder |
| Study years | 2023–2024 |
| Entry review | 2026-10-03 |
Participation
Check the study record or contact the study team for current recruitment and eligibility.
Study eligibility
Inclusion Criteria: * Stable Kidney Transplant Recipients * Stable Immunosupression Dose * Stable Renal Function * Resistant Urinary Infection with Positive UC Exclusion Criteria: * Rejection periods * Frail Patients
Study description
Urinary tract infections (UTIs) with extended-spectrum -lactamase (ESBL)-positive Enterobacteriums (ESBL-E) are a common infectious complication of renal transplant recipients, with 10% of patients suffering from UTIs with ESBL-E within the first year posttransplant. Moreover, recurrence rates of UTI caused by ESBL-E are almost three times higher than those by cephalosporin-susceptible Enterobacteriums demonstrating the decreased efficacy of antibiotics in the treatment of these UTIs.
Study registrations
| ClinicalTrials.gov | NCT05967130 |
|---|
Recorded study locations (1)
Locations listed in the study record; this does not confirm current recruitment or treatment outside the study. A site label may be older than the overall study status.
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Study ID | nct05967130 |
|---|